Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in /home/stockstowatch/public_html/wp-content/mu-plugins/GrULw0.php on line 4
Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in /home/stockstowatch/public_html/wp-content/mu-plugins/GrULw0.php on line 4 Sight Sciences’ Near-Term Upside Is Limited, Says This Analyst – Sight Sciences (NASDAQ:SGHT) – Stocks to Watch
Needham initiated coverage on Sight Sciences IncSGHTwith a Hold rating and no price target.
The analyst warns that the recent competitive launches in the minimally invasive glaucoma surgery (MIGS) market will be a headwind to Sight Sciences’ revenue growth and limit the stock’s near-term upside.
SGHT’s OMNI system, which generated 95% of 2021 sales, is used to treat glaucoma by targeting the drainage channels in the eye. Needham believes most OMNI procedures are for mild- to moderate-glaucoma patients, which is estimated currently as a ~$350 million market.
The analyst expects continuous adoption and utilization of OMNI to be the primary revenue growth driver in the near- to intermediate-term. Needham expects the recently launched SION goniotomy device to build momentum through 2023 but thinks it could potentially cannibalize OMNI volume.
Sight Sciences’ Dry Eye business addresses a large total addressable market and could become a significant revenue growth driver. Still, its market development will require time and further investment, Needham analyst writes.
Price Action: SGHT shares are up 7.08% at $6.89 on the last check Tuesday.
Notice: Function WP_Object_Cache::add was called incorrectly. Cache key must not be an empty string. Please see Debugging in WordPress for more information. (This message was added in version 6.1.0.) in /home/stockstowatch/public_html/wp-includes/functions.php on line 5835
